Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Tecentriq“
Suchtreffer
Begriffe & Kennungen
Tecentriq · 4.8 · Across pooled datasets for patients treated with atezolizumab monotherapy (N=3 460) and with combination thera
Eintrag öffnenTecentriq · 4.8 · Adrenal insufficiency
Eintrag öffnenTecentriq · 4.8 · Adrenal insufficiency
Eintrag öffnenTecentriq · 4.8 · Adrenal insufficiency occurred in 0.5% (25/5 039) of patients who received atezolizumab monotherapy. The media
Eintrag öffnenTecentriq · 4.8 · Adrenal insufficiency occurred in 0.5% (25/5 039) of patients who received atezolizumab monotherapy. The media
Eintrag öffnenTecentriq · 4.8 · Atezolizumab monotherapy Atezolizumab in combination therapy Infections and infestations Very common urinary t
Eintrag öffnenTecentriq · 4.8 · Atezolizumab monotherapy Atezolizumab in combination therapy Infections and infestations Very common urinary t
Eintrag öffnenTecentriq · 4.8 · Colitis occurred in 1.2% (62/5 039) of patients who received atezolizumab monotherapy. The median time to onse
Eintrag öffnenTecentriq · 4.8 · Colitis occurred in 1.2% (62/5 039) of patients who received atezolizumab monotherapy. The median time to onse
Eintrag öffnenTecentriq · 4.8 · Description of selected adverse reactions
Eintrag öffnenTecentriq · 4.8 · Diabetes mellitus
Eintrag öffnenTecentriq · 4.8 · Diabetes mellitus occurred in 0.6% (30/5 039) of patients who received atezolizumab monotherapy. The median ti
Eintrag öffnenTecentriq · 4.8 · Diabetes mellitus occurred in 0.6% (30/5 039) of patients who received atezolizumab monotherapy. The median ti
Eintrag öffnenTecentriq · 4.8 · Diabetes mellitus occurred in 2.0% (10/493) of HCC patients who received atezolizumab in combination with beva
Eintrag öffnenTecentriq · 4.8 · Diabetes mellitus occurred in 2.0% (10/493) of HCC patients who received atezolizumab in combination with beva
Eintrag öffnenTecentriq · 4.8 · Facial paresis occurred in < 0.1% (1/5 039) of patients who received atezolizumab monotherapy. The time to ons
Eintrag öffnenTecentriq · 4.8 · Facial paresis occurred in < 0.1% (1/5 039) of patients who received atezolizumab monotherapy. The time to ons
Eintrag öffnenTecentriq · 4.8 · Further details on serious adverse reactions are provided in section 4.4.
Eintrag öffnenTecentriq · 4.8 · Further details on serious adverse reactions are provided in section 4.4.
Eintrag öffnenTecentriq · 4.8 · Guillain-Barré syndrome and demyelinating polyneuropathy
Eintrag öffnen